About Ethypharm
Ethypharm is a company based in Saint-cloud (France) founded in 1977 was acquired by PAI Partners in May 2016.. Ethypharm has raised $248.09 million across 5 funding rounds from investors including Goldman Sachs, J P Morgan and Biovail. Ethypharm has completed 2 acquisitions, including DB Ashbourne and Martindale Pharma. Ethypharm offers products and services including CNS Medicines and Hospital Injectables. Ethypharm operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Saint-cloud, France
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ethypharm Group
-
Annual Revenue
$167.87 M (USD)-4as on Dec 31, 2016
-
Net Profit
$23.52 M (USD)85as on Dec 31, 2016
-
EBITDA
-
Total Equity Funding
$248.09 M (USD)
in 5 rounds
-
Latest Funding Round
$557.3 K (USD), Grant
Dec 21, 2023
-
Investors
Goldman Sachs
& 5 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
DB Ashbourne
& 1 more
-
Acquired by
PAI Partners
(May 07, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ethypharm
Ethypharm offers a comprehensive portfolio of products and services, including CNS Medicines and Hospital Injectables. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments for severe pain and addiction disorders
Medications for critical care situations
Unlock access to complete
Software Development Team
23 people
Product Management Team
10 people
Leadership Team
9 people
Sales and Marketing
7 people
Responsable Team
7 people
Human Resources and Administration
7 people
Head Team
6 people
Senior Team
6 people
Unlock access to complete
Funding Insights of Ethypharm
Ethypharm has successfully raised a total of $248.09M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $557.3 thousand completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $557,299
-
First Round
First Round
(15 Apr 2002)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Grant - Ethypharm | Valuation |
investors |
|
| Apr, 2021 | Amount | Grant - Ethypharm | Valuation |
investors |
|
| Sep, 2015 | Amount | Debt – Conventional - Ethypharm | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ethypharm
Ethypharm has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, J P Morgan and Biovail. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment banking services are delivered across multiple financial sectors.
|
Founded Year | Domain | Location | |
|
Astorg is engaged in private equity investment management.
|
Founded Year | Domain | Location | |
|
Private equity investments in market-leading companies across global sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ethypharm
Ethypharm has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include DB Ashbourne and Martindale Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Procurement platform for generic medicines is provided by DB Ashbourne.
|
2010 | ||||
|
Membrane-based humidifiers for fuel cell systems are manufactured.
|
1787 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Ethypharm
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ethypharm Comparisons
Competitors of Ethypharm
Ethypharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ethypharm
Frequently Asked Questions about Ethypharm
When was Ethypharm founded?
Ethypharm was founded in 1977 and raised its 1st funding round 25 years after it was founded.
Where is Ethypharm located?
Ethypharm is headquartered in Saint-cloud, France.
Who is the current CEO of Ethypharm?
Bertrand Deluard is the current CEO of Ethypharm.
Is Ethypharm a funded company?
Ethypharm is a funded company, having raised a total of $248.09M across 5 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $331.67M, raised on Apr 15, 2002.
What is the annual revenue of Ethypharm?
Annual revenue of Ethypharm is $167.87M as on Dec 31, 2016.
What does Ethypharm do?
Ethypharm was founded in 1977 in Saint-Cloud, France, within the pharmaceutical sector. Drugs and drug delivery systems are developed to address pain and addiction. A portfolio including morphine, fentanyl, tramadol, oxycodone, etodolac, triamcinolone hexacetonide, and episil is maintained for pain management. Additional efforts target alcohol dependence, overdose prevention, and opioid replacement therapies, with operations centered in Europe.
Who are the top competitors of Ethypharm?
Ethypharm's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does Ethypharm offer?
Ethypharm offers CNS Medicines and Hospital Injectables.
How many acquisitions has Ethypharm made?
Ethypharm has made 2 acquisitions, including DB Ashbourne, and Martindale Pharma.
Who are Ethypharm's investors?
Ethypharm has 6 investors. Key investors include Goldman Sachs, J P Morgan, Biovail, Ministry of Economy, Finance and Industrial and Digital Sovereignty, and Astorg.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.